Catabasis Pharmaceuticals, Inc. (CATB): Price and Financial Metrics


Catabasis Pharmaceuticals, Inc. (CATB): $8.54

-0.64 (-6.97%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CATB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CATB Stock Price Chart Interactive Chart >

Price chart for CATB

CATB Price/Volume Stats

Current price $8.54 52-week high $47.82
Prev. close $9.18 52-week low $6.31
Day low $8.46 Volume 98,800
Day high $9.21 Avg. volume 491,246
50-day MA $9.82 Dividend yield N/A
200-day MA $13.56 Market Cap 33.34M

Catabasis Pharmaceuticals, Inc. (CATB) Company Bio


Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The company was incorporated in 2008 and is based in Cambridge, Massachusetts.


CATB Latest News Stream


Event/Time News Detail
Loading, please wait...

CATB Latest Social Stream


Loading social stream, please wait...

View Full CATB Social Stream

Latest CATB News From Around the Web

Below are the latest news stories about Catabasis Pharmaceuticals Inc that investors may wish to consider to help them evaluate CATB as an investment opportunity.

Astria Therapeutics to Present at Upcoming Investor Conferences

BOSTON, September 10, 2021--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the following upcoming virtual investor conferences:

Yahoo | September 10, 2021

Catabasis Renames As Astria Therapeutics With New Disease Focus

Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus. Catabasis has been dragging for several years, weighed down mainly by the failure of the edasalonexent program in Duchenne muscular dystrophy. After it failed in a late-stage study, Catabasis decided to discontinue the development of the drug altogether. Then, in February, Catabasis acquired another local company, a rare disease startup called Quellis Biosciences. Now, Cata

Yahoo | September 8, 2021

Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus

BOSTON, September 08, 2021--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. ("Astria" or the "Company"). The name Astria originates from the Greek word for star, reflecting the Company’s commitment to having patients serve as guiding stars. Astria’s mission is to bring hope with life-changing therapies to patients and families. Astria expects t

Yahoo | September 8, 2021

Do Institutions Own Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Shares?

The big shareholder groups in Catabasis Pharmaceuticals, Inc. ( NASDAQ:CATB ) have power over the company. Large...

Yahoo | September 2, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning!

William White on InvestorPlace | August 20, 2021

Read More 'CATB' Stories Here

CATB Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -30.23%
3-year -78.91%
5-year -89.38%
YTD N/A
2021 0.00%
2020 -63.79%
2019 35.24%
2018 -70.67%
2017 -58.73%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7529 seconds.